Workflow
安必平(688393) - 2020 Q3 - 季度财报
LBPMedicineLBPMedicine(SH:688393)2020-10-21 16:00

Financial Performance - Operating revenue for the first nine months increased by 5.75% year-on-year, amounting to CNY 264,639,058.28[6] - Net profit attributable to shareholders grew by 10.18% year-on-year, reaching CNY 66,376,047.17[6] - Total operating revenue for Q3 2020 reached ¥119,818,695.61, a 27.1% increase from ¥94,348,622.56 in Q3 2019[30] - Net profit for Q3 2020 was ¥33,639,133.69, representing a 17.4% increase compared to ¥28,543,221.50 in Q3 2019[31] - The total profit for Q3 2020 was ¥30,201,030.22, up from ¥26,093,850.01 in Q3 2019, reflecting a growth of 8.1%[35] - The company reported a total comprehensive income for Q3 2020 of ¥33,639,133.69, compared to ¥28,543,221.50 in Q3 2019, indicating a growth of 17.4%[36] Assets and Liabilities - Total assets increased by 130.41% year-on-year, reaching CNY 1,239,495,993.32[6] - The total assets of the company stood at ¥1,239,495,993.32, up from ¥537,961,728.25 year-over-year[24] - Total liabilities decreased to ¥89,882,155.46 from ¥93,334,074.16, reflecting improved financial stability[24] - Total liabilities as of Q3 2020 amounted to ¥119,279,769.51, up from ¥105,597,668.44 in the previous year[28] - Total current liabilities were reported at ¥53,065,135.17, a decrease from ¥57,761,738.81, indicating improved liquidity management[23] Shareholder Information - Net assets attributable to shareholders rose by 159.34% compared to the previous year, totaling CNY 1,149,601,367.46[6] - The total number of shareholders reached 10,537 by the end of the reporting period[12] - The top shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[12] - Shareholders' equity increased significantly to ¥1,149,613,837.86 from ¥444,627,654.09, showcasing strong retained earnings and capital growth[24] Cash Flow - The net cash flow from operating activities decreased by 27.88% year-on-year, totaling CNY 41,442,592.34[6] - Cash flow from financing activities showed a net increase of CNY 648,008,526.05, a significant improvement from a net outflow of CNY -19,219,250.00 in Q2 2020[39] - The cash flow from operating activities for the first three quarters of 2020 was ¥271,986,515.96, slightly down from ¥273,345,531.90 in the same period of 2019[37] Research and Development - R&D expenditure as a percentage of operating income increased by 1.18 percentage points to 6.60%[7] - Research and development expenses for Q3 2020 totaled ¥6,188,761.20, an increase of 16.4% from ¥5,311,490.58 in Q3 2019[30] - Research and development expenses for Q3 2020 were ¥4,513,963.91, an increase of 52.2% from ¥2,964,224.35 in Q3 2019[35] Investment Activities - The company reported a net cash flow from financing activities of ¥648,008,526.05, a significant increase compared to the previous year[16] - The company has invested ¥102,233,595.00 in construction projects, up from ¥81,192,580.35, highlighting ongoing expansion efforts[23] - The company received CNY 649,520,526.05 from investment in Q3 2020, compared to CNY 1,700,000.00 in the previous quarter[39] Market Strategy - The company is focused on expanding its market presence and enhancing product development strategies[18] - The company plans to continue expanding its market presence and invest in new product development[30] Other Financial Metrics - Basic and diluted earnings per share increased by 5.81% to CNY 0.91[7] - The weighted average return on net assets decreased by 1.92 percentage points to 12.53%[7] - Other income increased by 90.34% to ¥1,090,906.00, attributed to government subsidies and VAT refunds[16]